1Department of Internal Medicine, Healthcare Research Institute, Seoul National University Hospital Healthcare System Gangnam Center, Seoul, Korea
2Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
3Division of Gastroenterology, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA
Copyright © 2021 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of Interest: The authors have no potential conflicts of interest.
Funding
None.
Author Contributions
Conceptualization: Ji Hyun Song, Shai Friedland
Data curation: JHS, SF
Writing-original draft: JHS
Writing-review&editing: SF
Patients (n=58) | |
---|---|
Age, mean±SD | 67.50±7.38 |
Sex, n (%) | |
Female | 3 (5.2) |
Male | 55 (94.8) |
Endoscopic procedure, n (%) | |
CSP | 31 (53.4) |
CS-EMR | 27 (46.6) |
Antiplatelet, n (%) No | |
No | 31 (53.4) |
Aspirin | 24 (41.4) |
Others | 3 (5.2) |
Anticoagulant, n (%) | |
No | 48 (82.8) |
Warfarin | 3 (5.2) |
DOAC | 6 (10.3) |
Heparin | 1 (1.7) |
Comorbiditiesa), n (%) | |
No | 22 (37.9) |
Diabetes mellitus | 20 (34.5) |
Coronary artery disease | 14 (24.1) |
Atrial fibrillation | 7 (12.1) |
Chronic obstructive pulmonary disease | 4 (6.9) |
Others | 6 (10.3) |
Patients (n=58) | |
---|---|
Age, mean±SD | 67.50±7.38 |
Sex, n (%) | |
Female | 3 (5.2) |
Male | 55 (94.8) |
Endoscopic procedure, n (%) | |
CSP | 31 (53.4) |
CS-EMR | 27 (46.6) |
Antiplatelet, n (%) No | |
No | 31 (53.4) |
Aspirin | 24 (41.4) |
Others | 3 (5.2) |
Anticoagulant, n (%) | |
No | 48 (82.8) |
Warfarin | 3 (5.2) |
DOAC | 6 (10.3) |
Heparin | 1 (1.7) |
Comorbidities |
|
No | 22 (37.9) |
Diabetes mellitus | 20 (34.5) |
Coronary artery disease | 14 (24.1) |
Atrial fibrillation | 7 (12.1) |
Chronic obstructive pulmonary disease | 4 (6.9) |
Others | 6 (10.3) |
Total (n=100) | CSP (n=50) | CS-EMR (n=50) | p-value | |
---|---|---|---|---|
Polyp size (mm) | 6.39±1.29 | 6.28±1.21 | 6.50±1.36 | 0.395 |
Polyp type | 1.000 | |||
Protruded | 60 | 30 (60.0%) | 30 (60.0%) | |
Flat elevated | 40 | 20 (40.0%) | 20 (40.0%) | |
Location | 0.316 | |||
Right colon | 54 | 30 (60.0%) | 24 (48.0%) | |
Left colon | 46 | 20 (40.0%) | 26 (52.0%) | |
Segment bowel preparation | 0.360 | |||
1 | 1 | 0 (0.0%) | 1 (2.0%) | |
2 | 31 | 18 (36.0%) | 13 (26.0%) | |
3 | 68 | 32 (64.0%) | 36 (72.0%) | |
Resection | 0.495 | |||
Piecemeal | 2 | 0 (0.0%) | 2 (4.0%) | |
En bloc | 98 | 50 (100.0%) | 48 (96.0%) | |
Grossly complete resection | 0.678 | |||
Not clear | 6 | 4 (8.0%) | 2 (4.0%) | |
Yes | 94 | 46 (92.0%) | 48 (96.0%) | |
Total procedure time (sec) | 50.95±36.70 | 23.14±19.05 | 78.76±27.94 | <0.001 |
Resection time (sec) | 23.40±18.54 | 23.14±19.05 | 23.66±18.21 | 0.889 |
Bleeding time (sec) | 38.73±33.00 | 36.94±29.18 | 40.52±36.64 | 0.590 |
Pathologic diagnosis | 0.204 | |||
Hyperplastic polyp | 9 | 7 (14.0%) | 2 (4.0%) | |
Serrated adenoma | 4 | 1 (2.0%) | 3 (6.0%) | |
Tubular adenoma | 79 | 37 (74.0%) | 42 (84.0%) | |
Others | 8 | 5 (10.0%) | 3 (6.0%) | |
Antiplatelet agent | 0.025 | |||
No | 58 | 35 (70.0%) | 23 (46.0%) | |
Yes | 42 | 15 (30.0%) | 27 (54.0%) | |
Anticoagulant | 0.393 | |||
None | 81 | 39 (78.0%) | 42 (84.0%) | |
Wafarin | 5 | 4 (8.0%) | 1 (2.0%) | |
DOAC | 13 | 6 (12.0%) | 7 (14.0%) | |
Heparin | 1 | 1 (2.0%) | 0 (0.0%) | |
Immediate bleeding | 0.269 | |||
No or minor | 92 | 48 (96.0%) | 44 (88.0%) | |
Need hemostasis | 8 | 2 (4.0%) | 6 (12.0%) | |
Delayed bleeding | 1.000 | |||
No | 98 | 49 (98.0%) | 49 (98.0%) | |
Yes | 2 | 1 (2.0%) | 1 (2.0%) | |
Perforation | ||||
No | 100 | 50 (100.0%) | 50 (100.0%) |
No bleeding (n=91) | Bleeding (n=9) | OR | 95% CI | p-value | |
---|---|---|---|---|---|
Age | 66.22±7.51 | 69.33±5.39 | 1.066 | 0.963–1.179 | 0.216 |
Endoscopic procedure | 0.100 | ||||
CSP | 48 (96.0) | 2 (4.0) | Reference | ||
CS-EMR | 43 (86.0) | 7 (14.0) | 3.907 | 0.770–19.831 | |
Antiplatelet | 0.583 | ||||
No | 52 (89.7) | 6 (10.3) | Reference | ||
Yes | 39 (92.9) | 3 (7.1) | 0.667 | 0.157–2.833 | |
Anticoagulant | <0.001 | ||||
No | 79 (97.5) | 2 (2.5) | Reference | ||
Warfarin | 4 (80.0) | 1 (20.0) | 9.875 | 0.732–133.240 | |
DOAC | 8 (61.5) | 5 (38.5) | 24.688 | 4.106–148.432 | |
Heparin | 0 (0.0) | 1 (100.0) | - | - | |
Polyp size (mm) | 6.30±1.25 | 7.33±1.32 | 1.740 | 1.060–2.858 | 0.029 |
Polyp type | 0.267 | ||||
Protruded | 53 (88.3) | 7 (11.7) | Reference | ||
Flat elevated | 38 (95.0) | 2 (5.0) | 0.398 | 0.078–2.025 | |
Location | 0.063 | ||||
Right colon | 52 (96.3) | 2 (3.7) | Reference | ||
Left colon | 39 (84.8) | 7 (15.2) | 4.667 | 0.919–23.708 | |
Total procedure time (sec) | 49.01±35.79 | 70.56±42.24 | 1.014 | 0.997–1.032 | 0.102 |
Resection time (sec) | 23.70±19.09 | 20.33±11.90 | 0.987 | 0.940–1.036 | 0.987 |
OR | 95% CI | |
---|---|---|
Endoscopic procedure | ||
CSP | Reference | |
CS-EMR | 10.420 | 0.768–141.324 |
Anticoagulant | ||
No | Reference | |
Warfarin | 42.334 | 1.006–1,781.758 |
DOAC | 35.244 | 3.853–322.397 |
Polyp size (mm) | 2.188 | 0.970–4.935 |
Location | ||
Right colon | Reference | |
Left colon | 3.530 | 0.417–29.875 |
CS-EMR, cold snare endoscopic mucosal resection; CSP, cold snare polypectomy; DOAC, direct-acting oral anticoagulants; SD, standard deviation. Some patients have more than one disease.
CS-EMR, cold snare endoscopic mucosal resection; CSP, cold snare polypectomy; DOAC, direct-acting oral anti-coagulants.
CI, confidence interval; CS-EMR, cold snare endoscopic mucosal resection; CSP, cold snare polypectomy; DOAC, direct-acting oral anticoagulants; OR, odds ratio.
Adjusted by endoscopic procedure, anticoagulant, polyp size, and location. CI, confidence interval; CS-EMR, cold snare endoscopic mucosal resection; CSP, cold snare polypectomy; DOAC, direct-acting oral anticoagulants; OR, odds ratio.